Travere Therapeutics (TVTX) Cash & Equivalents (2013 - 2026)

Travere Therapeutics has reported Cash & Equivalents for 14 years, with the latest figure at $78.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 26.6% year-over-year to $78.4 million; the trailing twelve-month figure through Mar 2026 stood at $78.4 million (up 26.6% YoY), and the FY2025 full-year result was $93.0 million, up 58.94% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $78.4 million, down from $93.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $256.6 million in Q1 2022, with the low at $32.3 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $98.5 million across 5 years, with a median of $75.2 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 74.76% — and 2025, when it jumped 204.68%.
• Travere Therapeutics' Cash & Equivalents stood at $61.7 million in 2022, then fell by 5.69% to $58.2 million in 2023, then gained by 0.62% to $58.5 million in 2024, then jumped by 58.94% to $93.0 million in 2025, then decreased by 15.77% to $78.4 million in 2026.
• The last three Cash & Equivalents figures came in at $78.4 million (Q1 2026), $93.0 million (Q4 2025), and $110.9 million (Q3 2025), per Business Quant data.